v3.10.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Revenues $ 651 $ 153 $ 696 $ 275
Operating expenses:        
Research and development (related party of $285, $197, $544 and $373), net of grant income of $37, $0, $37 and $44 1,273 993 2,397 1,978
General and administrative (related party of $311, $181, $572 and $387) 3,393 2,587 6,264 5,085
Total operating expenses 4,666 3,580 8,661 7,063
Operating loss (4,015) (3,427) (7,965) (6,788)
Other income (expense):        
Interest expense (related party of $476, $479, $952 and $959) (476) (479) (952) (959)
Interest income 23 4 44 9
Royalty income (expense) (2) 2 4 11
Total other income (expense) (455) (473) (904) (939)
Consolidated net loss (4,470) (3,900) (8,869) (7,727)
Net loss attributable to noncontrolling interest 1 1 2 2
Net loss attributable to iBio, Inc. (4,469) (3,899) (8,867) (7,725)
Preferred stock dividends (65) (65) (131) (131)
Net loss available to iBio, Inc. (4,534) (3,964) (8,998) (7,856)
Comprehensive loss:        
Consolidated net loss (4,470) (3,900) (8,869) (7,727)
Other comprehensive income (loss) - foreign currency translation adjustments 1 0 0 0
Comprehensive loss $ (4,469) $ (3,900) $ (8,869) $ (7,727)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.24) $ (0.41) $ (0.49) $ (0.82)
Weighted-average common shares outstanding - basic and diluted 18,688 9,661 18,291 9,613

Source